Evidence map›Paper›PMID 18410326›Full record

Trial reportJournal of the American Geriatrics Society2008

Randomized, placebo-controlled trial of the cognitive effect, safety, and tolerability of oral extended-release oxybutynin in cognitively impaired nursing home residents with urge urinary incontinence.

Thomas E Lackner, Jean F Wyman, Teresa C McCarthy, Melinda Monigold, Cynthia Davey

Abstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Journal of the American Geriatrics Society, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 12 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 12 pooled it
6.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 12 syntheses or guidelines pooled it, 124 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Interventions for preventing delirium in hospitalised non-ICU patients.The Cochrane database of systematic reviews · 2016
    Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Overactive bladder - 18 years - Part II.International braz j urol : official journal of the Brazilian Society of Urology
    Pooled it
  12. Pooled it
  13. Trial
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Thomas E LacknerDepartment of Experimental and Clinical Pharmacology and Institute for the Study of Geriatric Pharmacotherapy, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota 55455, USA. lackn001@umn.edu
Jean F Wyman
Teresa C McCarthy
Melinda Monigold
Cynthia Davey
University of Minnesota System · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesDetermine the cognitive effect, safety, and tolerability of oral extended-release oxybutynin in cognitively impaired older nursing home residents with urge urinary incontinence.

designRandomized, double-blinded, placebo-controlled trial.

settingTwelve skilled nursing homes.

participantsFifty women aged 65 and older with urge incontinence and cognitive impairment.

interventionFour-week treatment with once-daily oral extended-release oxybutynin 5 mg or placebo. MEASUREMENTS: Withdrawal rates and delirium or change in cognition from baseline at 1, 3, 7, 14, 21, and 28 days after starting treatment using the Confusion Assessment Method (CAM), Mini-Mental State Examination (MMSE), and Severe Impairment Battery (SIB). The Brief Agitation Rating Scale, adverse events, falls incidence, and serum anticholinergic activity change with treatment were also assessed.

resultsParticipants' mean age +/-standard deviation was 88.6+/-6.2, and MMSE baseline score was 14.5+/-4.3. Ninety-six percent of subjects receiving oxybutynin (n=26) and 92% receiving placebo (n=24) completed treatment (P=.50). The differences in mean change in CAM score from baseline to all time points were equivalent between the oxybutynin and placebo groups. Delirium did not occur in either group. One participant receiving oxybutynin was withdrawn because of urinary retention, which resolved without treatment. Mild adverse events occurred in 38.5% of participants receiving oxybutynin and 37.5% receiving placebo (P=.94).

conclusionShort-term treatment using oral extended-release oxybutynin 5 mg once daily was safe and well tolerated, with no delirium, in older female nursing home participants with mild to severe dementia. Future research should investigate different dosages and long-term treatment.

Indexed as

Accidental FallsAdministration, OralAgedAged, 80 and overCognitionConfusionDelayed-Action PreparationsDeliriumDose-Response Relationship, DrugDouble-Blind MethodDrug-Related Side Effects and Adverse ReactionsFemaleHomes for the AgedHumansMandelic AcidsMental Status ScheduleDelayed-Action PreparationsMandelic Acidsoxybutynin

Identifiers

PMID18410326
OpenAlexW1600148322

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.